John H. Heiligenstein
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Attention Deficit Hyperactivity Disorder, Treatment of Major Depression, Child and Adolescent Psychosocial and Emotional Development, Mental Health Treatment and Access, Electroconvulsive Therapy Studies
Most-Cited Works
- → Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial(2002)575 cited
- → Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder(2002)336 cited
- → Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial(2001)322 cited
- → Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label Trial(2002)294 cited
- → Recovery from depression, work productivity, and health care costs among primary care patients(2000)268 cited
- → Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults(2003)191 cited
- → Validation of the ADHD Rating Scale as a clirlician administered and scored instrument(2001)185 cited
- → A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer(1998)165 cited
- → An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder(2001)150 cited